Compare Amcor PLC (AMCR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Recursion Pharmaceuticals Inc — how do they compare? Amcor PLC trades at $46.75 (market cap $21.92B), while Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.81B). The key difference: Amcor PLC is far larger — about 12.1× Recursion Pharmaceuticals Inc's market cap, and Amcor PLC pays a 5.49% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMCR | RXRX | |
|---|---|---|
Market Cap | $21.92B | $1.81B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $6.79 |
52-Week Low | $36.69 | $2.84 |
Enterprise Value | $37.03B | $1.33B |
Dividend Yield | 5.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $47.11, down 1.57% today, near the consensus price target of $47.00. Recent quarters show consistent earnings beats, with Q4 2026 revenue up 26% year-over-year to $6.4 billion, driven by the Berry acquisition (PRNewsWire, Aug 12, 2026). Technical indicators signal a bullish trend, while valuation ratios like P/E of 38.07 appear elevated relative to historical margins. The company maintains a solid dividend, with a $0.65 payment scheduled for June 2026.
Outlook is cautiously optimistic given strong revenue growth and analyst buy ratings (64% consensus), but risks include high debt levels and margin pressure, with net income margin declining to 3.06% in 2025. Investors should weigh acquisition benefits against integration challenges and cyclical demand headwinds in packaging markets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
